Kag: I'm glad you took the time to research the SEC enforcement process, but you are misinterpreting your findings. Your statement that "Companies slapped with a SEC trading suspension are not allowed a Wells process" and the supporting paragraph you provided is 100% irrelevant in the case of BOCX because the trading suspension was so short and, more importantly, the SEC NEVER FILED A WELLS NOTICE. Thus, any discussion on BOCX's inability to make a Wells Submission is 100% irrelevant.
Your comment that the trading suspension "was likely the intended extent of SEC's action aganist BOCX" is even more absurd. The comment assumes that the SEC knew ahead of time what they would find during the informal investigation (which is really a glorified word for "discovery process" in legal parlance). If the SEC found serious wrongdoing on the part of the d/o's, believe me the trading suspension would not have been the extent of the enforcement action! You gotta be kidding me!
No amount of academic circle jerk will change the fact that the SEC halted the stock, did discovery, and quietly went away. If you believe that they will one day wake up and bring charges years and years later, sell your stock because we'd tank if that happened. Enough on this please...go back to class and pay attention this time.
FYI BOCX's updated shareholders in the following:
BioCurex On Its Way Back To The OTC:BB
RICHMOND, British Columbia, July 22, 2004 (PRIMEZONE) -- BioCurex, Inc. (Pink Sheets:BOCX) provides a Company update on its effort to reestablish trading on the NASD OTC:BB:
Three months ago BioCurex underwent an investigation by the SEC. Following a sudden increase in the price of our stock, the Commission decided it was in the best interests of our investors to halt trading of BOCX shares for 10 days based on "questions regarding the accuracy of assertions by BioCurex and others, in press releases and e-mails to investors concerning, among other things, (1) a study confirming the effectiveness of its primary product and (2) approval of its main product by the Food and Drug Administration". The company immediately clarified any semantics in reference to the FDA classification of its Histo-RECAF technology and stood firmly by its reported results. Further, in an unprecedented move, a complete and detailed description of the raw scientific data including the statistical analysis of our lung cancer study was posted on the company web site for everyone to view.
Those same results, along with other studies, were subsequently presented in two congresses that gather international specialists in the field of cancer markers. The presentations elicited a significant amount of interest by very knowledgeable persons as outlined in a previous news release. It should be emphasized that we would not have gone to those congresses if we did not have complete confidence in our results, nor would those results have passed the scrutiny of the international scientific community in the field, if the results had not been well substantiated and valid -- which they were.
We have fully cooperated with the SEC, while standing by our claims, which are valid.
The trading suspension caused the company's shares to be removed from the OTCBB. Since April 23rd 2004, our shares have traded in the "Pink Sheets", an unorganized market where actual Bid and Offer at any given time are not always available to all of our investors.
News 
Market Data 
Discover 
AI
